文献速递眼底病与葡萄膜炎眼整形与眼眶

107例虹膜黑色素瘤患者的质子束治疗

Proton Beam Therapy for Iris Melanomas in 107 Patients.
PubMed 文献 · Ophthalmology · 2017-11-08

这项回顾性研究纳入来自3家区域性眼科中心、于1996年至2015年间在同一质子治疗机构接受治疗的107例虹膜黑色素瘤患者,中位随访49.5个月。结果显示,5年累积复发率为7.5%,无患者发生转移或死于虹膜黑色素瘤,59.4%的患者视力改善,但白内障等并发症较常见;质子治疗在虹膜黑色素瘤中显示出疗效且发病率有限。

要点

  • 107例虹膜黑色素瘤患者接受质子治疗,中位随访49.5个月,5年累积复发率为7.5%。
  • 无患者发生转移或死于虹膜黑色素瘤,59.4%的患者视力改善。
  • 无白内障或人工晶状体植入的54例患者中,57.4%发生白内障;继发性青光眼占7.6%。

核心结论

  • 质子治疗在虹膜黑色素瘤中显示出疗效,且发病率有限。

研究设计与样本

  • 回顾性研究,纳入来自3家区域性眼科中心、1996年至2015年间转诊至并在同一质子治疗机构接受治疗的107例虹膜黑色素瘤患者。

主要发现

  • 中位随访49.5个月,107例患者中5例出现局部复发,中位复发时间36.3个月,5年累积复发率为7.5%。
  • 5例复发患者均显示累及虹膜角膜角(P = 0.056);弥漫性虹膜黑色素瘤复发风险更高(P = 0.044)。
  • 4例为野外复发,1例为角部复发;3例再次接受质子治疗,另2例(1例为T1b期病变,1例为弥漫性T3期病变)接受二期眼球摘除。
  • 无患者发生转移或死于虹膜黑色素瘤;59.4%的患者视力改善(n = 60/101)。
  • 诊断时无白内障或人工晶状体的54例患者中,57.4%(n = 31)发生白内障;继发性青光眼占7.6%(n = 8),葡萄膜炎占4.7%(n = 5),前房积血占3.7%(n = 4);除5例外,并发症均轻微、短暂且不限制视力,5例严重青光眼(含1例葡萄膜炎)伴视力恶化。

关键数值与推荐

  • 5年累积复发率为7.5%;5例复发患者均累及虹膜角膜角(P = 0.056),弥漫性虹膜黑色素瘤复发风险更高(P = 0.044)。
  • 视力改善见于59.4%的患者(n = 60/101);无白内障或人工晶状体的54例患者中白内障发生率为57.4%(n = 31)。
  • 继发性青光眼占7.6%(n = 8),葡萄膜炎占4.7%(n = 5),前房积血占3.7%(n = 4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report on the clinical characteristics and outcomes for patients with iris melanoma using proton therapy. DESIGN: Retrospective study. PARTICIPANTS: One hundred seven patients with iris melanoma from 3 regional ophthalmologic centers. METHODS: A retrospective study was conducted for iris melanoma patients from 3 regional ophthalmologic centers referred to and treated at a single proton therapy facility between 1996 and 2015. MAIN OUTCOME MEASURES: At each follow-up visit, examinations included measurement of best-corrected VA, slit-lamp, examination, indirect ophthalmoscopy, and ultrasound biomicroscopy. RESULTS: With a median follow-up of 49.5 months, 5 of 107 patients experienced a local relapse within a median of 36.3 months. The cumulative incidence of relapse was 7.5% at 5 years. All 5 patients showed involvement of the iridocorneal angle (P = 0.056). Diffuse iris melanoma showed a higher risk of relapse (P = 0.044). Four patients showed out-of-field relapse and 1 showed angular relapse. Three patients were retreated with proton therapy, whereas 2 other patients, one with T1b disease and another with diffuse T3 disease, underwent secondary enucleation. None of the patients experienced metastases nor died of iris melanoma. Vision improved in 59.4% of patients (n = 60/101). However, cataracts occurred in 57.4% of the 54 patients (n = 31) without cataract or implant at diagnosis. Secondary glaucoma was reported in 7.6% of the patients (n = 8), uveitis in 4.7% (n = 5), and hyphema in 3.7% (n = 4). All but 5 cases of complications were mild, transient, and not sight limiting after treatment. Five cases of glaucoma, including 1 with uveitis, were severe and associated with visual deterioration. CONCLUSIONS: Proton therapy showed efficacy and limited morbidity in iris melanomas.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Thariat J, Rahmi A, Salleron J, et al. Proton Beam Therapy for Iris Melanomas in 107 Patients. Ophthalmology. 2017. PMID: 29128229. doi:10.1016/j.ophtha.2017.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。